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Abstract
Purpose: This project was anticipated to demonstrate an increase in the number of those
diagnosed with BED according to Diagnostic and Statistical Manual (DSM) 5 criteria, diagnosed
with ICD-10 code F50.8 or R63.2 and treated according to best practice guidelines.
Background: Binge eating disorder (BED) is the most common eating disorder in the United
States, more than both anorexia and bulimia combined. It affects 3.5 percent of women, 2
percent of men and 30 percent of those seeking weight management.
Design: This evidenced-based project consisted of a retrospective analysis of 150 patients seen
in a weight management clinic setting since implementing the ICD-10 coding system 02/09/16.
Findings: Results demonstrated the prevalence of BED in this weight management center was
27.5%, 44% were diagnosed with an ICD 10 code, and approximately 20% were provided with
evidence based treatments.
Clinical Implications: Understanding the prevalence of BED demonstrates the need for
increased screening methods to optimize the likelihood patients obtain empirically supported
treatment.
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Background
When discussing eating disorders, most individuals are relatively familiar with both
anorexia nervosa and bulimia nervosa. Surprisingly, the less familiar condition, binge eating
disorder (BED), is in fact more common than both anorexia and bulimia combined. BED affects
approximately 3.5 percent of women, 2 percent of men and at least 30 percent of those seeking
weight management treatment (Binge Eating Disorder Association [BEDA], 2017).
Binge eating is not a choice and is not the cause of obesity, although up to 70 percent of
those with BED are obese (BEDA, 2017). It is an emotional and behavioral disorder according to
the American Psychological Association (APA). Previously, under the Diagnostic and Statistical
Manual of Mental Disorders fourth edition (DSM-IV) released in 1994, BED was itemized under
Appendix B as an ambiguous diagnosis of “Eating Disorder Not Otherwise Specified.” Since
then, numerous studies have been conducted and published supporting BED as an independent
diagnosis. In the recently updated DSM-5, released in 2013, BED became an independent
diagnosis with a modification in its qualifying criteria. In addition, a recent update to the
International Statistical Classification of Diseases 10 (ICD-10) has included billable codes for
binge eating disorder including F50.8 (BED) and R63.2 (polyphagia).
The Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) has
specific criteria that must be met for diagnosis. An episode of binge eating must involve both
recurrent episodes of binge eating in discrete periods of time and eating large quantities of food,
more than an average person may eat in the same amount of time in addition to feeling a lack of
control when eating (APA, 2010). Furthermore, persons must meet at least three of the
associated criteria including feeling uncomfortably full, eating large amounts when not
physically hungry, eating more rapidly than normal, eating alone out of embarrassment and/or
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feeling disgusted, depressed, ashamed or guilty after overeating (APA, 2010). These episodes
must occur at least once a week over a three-month period and cannot be associated with
compensatory actions such as purging or excessive exercise as this falls under the realm of
bulimia (see Table 1).
Not only does binge eating disorder result in behavioral issues such as distortional body
image, anxiety, depression and substance abuse (Mehler, et al, 2010), but BED sufferers are also

DSM-5 Diagnostic Criteria for Binge-Eating Disorder
A. Recurrent episodes of binge eating. An episode of binge eating is characterized by both of
the following:
1. Eating, in a discrete period of time (for example, within any 2-hour period), an
amount of food that is definitely larger than what most people would eat in a similar
period of time under similar circumstances
2. A sense of lack of control over eating during the episode (eg, a feeling that one
cannot stop eating or control what or how much one is eating)
B. The binge-eating episodes are associated with 3 (or more) of the following:
1. Eating much more rapidly than normal
2. Eating until feeling uncomfortably full
3. Eating large amounts of food when not feeling physically hungry
4. Eating alone because of feeling embarrassed by how much one is eating
5. Feeling disgusted with oneself, depressed, or very guilty afterwards
C. Marked distress regarding binge eating is present
D. The binge eating occurs, on average, at least once a week for 3 months
E. The binge eating is not associated with the recurrent use of inappropriate compensatory
behavior as in bulimia nervosa (for example, purging) and does not occur exclusively during
the course of bulimia nervosa or anorexia nervosa
Specify current severity:
The minimum level of severity is based on the frequency of episodes of binge eating.
Mild: 1-3 binge-eating episodes per week.
Moderate: 4-7 binge-eating episodes per week.
Severe: 8-13 binge-eating episodes per week.
Extreme: 14 or more binge-eating episodes per week.
American Psychological Association (2010).
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at increased risk for several comorbid conditions such as Type 2 diabetes, hypertension,
dyslipidemia, osteoarthritis and sleep apnea (Tanofsky-Kraff, et al, 2012). This raises the level of
care needed to improve mortality and quality of life of those with BED.
Evidence-based treatments for binge eating disorder include, both pharmacologic and
psychotherapeutic modalities. Of the psychotherapeutic therapies, cognitive behavioral therapy,
dialectic behavior therapy and interpersonal psychotherapy have been associated with binge
frequency reduction rates and significant abstinence rates (APA, 2010). The anti-epileptic drug,
topiramate has been studied and shown to reduce hunger, promote weight loss, and demonstrated
a significant reduction in binge episodes and impulsivity (Amiato, Ottone, Daga & Fassino,
2015). Currently, lisdexamfetamine dimesylate (Vyvanse) is the only FDA-approved medication
for the treatment of BED. According to Saules, Carey, Carr and Sienko (2015), studies of
lisdexamfetamine showed a significant reduction in number of binge days, with strong effect
sizes.
Overall, this project is anticipated to demonstrate an increase in the number of patients
identified with BED in congruence with the recent updates to DSM-5 criteria, ICD-10 codes, and
an increase in evidence-based treatment methods provided to those of those diagnosed with
BED.
Purpose/Aims
The purpose of this evidenced-based practice project was to examine the prevalence of
BED determined by DSM-5 criteria, whether these patients were assigned ICD-10 codes F50.8
or R63.2, determine severity and demographics associated with those with BED, compare level
of comorbidities in those with and without BED as well as determine whether evidence-based
treatments were being utilized.
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Literature Review
To accomplish the objective of determining if evidence-based treatment for binge eating
disorder was being used, a systematic literature search was conducted using MEDLINE,
CINHAL, and PUBMED using the terms ‘Binge Eating Disorder,’ ‘BED’ and ‘Binge eating
disorder treatment.’ The Agency for Healthcare Research and Quality (AHRQ), APA and
various eating disorder association websites were also searched. A total of 25 articles were
reviewed, all of which were relevant, with a total of six used to support latest evidence-based
treatments.
According to APA guidelines (2012), the evidence-based treatment recommendations for
BED include cognitive behavioral therapy, dialectic behavior therapy and interpersonal
psychotherapy. These treatment modalities were associated with binge frequency reduction and
significant binge abstinence rates during active treatment. Cognitive approaches focusing on selfacceptance and healthy lifestyle, not weight loss, were effective in reducing binge eating and
depression, anxiety, body dissatisfaction as well as cholesterol and blood pressure (Tanco,
Linden, & Earle, 1998). A retrospective chart review analyzing the use of the SSRI, venlafaxine,
in obese patients with binge eating disorder reported positive effects on binge eating, weight and
mood (Malhotra, King, Welge, Brusman-Lovins & McElroy, 2002). Two studies, one a
retrospective review of patients with affective disorders and co-occurring binge eating disorder
(Shapira, Goldsmith & McElroy, 2000) and a randomized, double-blind, placebo-controlled
study (McElroy, et al, 2003), found topiramate to be effective for both binge suppression and
weight loss.
In 2016, the AHRQ conducted a systematic review of evidence on the effectiveness of
binge eating treatments. In regards to psychological and behavioral interventions, therapist-led
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CBT reduced binge-eating frequency and increased binge-eating abstinence (AHRQ, 2016). In
regards to pharmacological interventions, a meta-analysies by McElroy, et al (2015) showed
substantial evidence that lisdexamfetamine increased binge-eating abstinence. Second-generation
antidepressants also increased binge-eating abstinence but also reduced binge-eating frequency
as well as eating-related obsessions and compulsions (AHRQ, 2016). A randomized, placebocontrolled trial by McElroy, et al (2007) produced added evidence that topiramate reduced bingeeating frequency, eating-related obsessions and compulsions, and weight.
A meta-analysis conducted by Vocks, et al (2010), comprising 38 studies with a total of
1973 participants, demonstrated that psychotherapy and structured self-help based on cognitive
behavioral interventions, were found to have large effects on the reduction of binge eating. The
study also demonstrated that the integration of SSRI medication showed moderate binge-eating
episode reduction.
Additionally, a recent systematic review and meta-analysis conducted by Brownley, et al
(2016), which analyzed 34 trials, determined that cognitive behavioral therapy,
lisdexamfetamine, second generation antidepressants and topiramate were effective in reducing
binge eating episodes and related psychological conditions. This study further demonstrated that
both lisdexamfetamine and topiramate were effective in reducing weight in adults with bingeeating disorder.
A literature review by Saules, Carey, Carr and Sienko (2015) also determined that
cognitive behavioral therapy is the most well-established and empirically supported treatment for
BED. They further found that a central nervous system stimulant, lisdexamfetamine dimesylate,
significantly reduced the number of binge days. Aminato, Ottone, Daga and Fassino (2015)
determined topiramate was effective in reducing impulsivity, binge episodes and thus reducing
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hunger and promoting weight loss.
Project Plan Process
The Iowa Model was utilized to guide this project in a weight management clinic setting.
This evidenced-based project consists of a retrospective review of 150 patient medical records
seen in an outpatient weight management clinic setting since the clinic implemented ICD-10
coding from February 09, 2016 through November 2016. Twelve patients were excluded as they
met some criteria of both BED patients and those without BED. A total of 138 patients were
included in this study. Data was analyzed to determine the prevalence of BED determined by
DSM-5 criteria, whether these patients were assigned the ICD-10 code F50.8 or R63.2, BED
severity distribution of patients, demographics associated with those with BED, a comparison of
comorbidities of those with or without BED as well as the determination if evidence-based
treatments are being provided.
Results
After conducting a thorough data analysis, it was determined that the prevalence of binge
eating disorder in this weight management center was 27.5%, which is comparable to the results
of the APA at 30 percent of those seeking weight management (APA, 2010). Demographics of
the 38 patients meeting criteria for BED include an average age of 52.8 years old, 52.6 percent
were male and 47.3 percent were female. The majority of those suffering from BED were
Caucasian at 73.7 percent, 18.4 percent were Hispanic and the remaining 7.9 were a combination
of other races. The average weight of the 38 BED patients was 263.58 with a mean body mass
index of 40.93, which falls in the severe obesity category. Of the 38 patients who met DSM 5
criteria for BED, 14 had 1-3 binge-eating episodes per week (mild), 20 had 4-7 episodes per
week (moderate) and 4 had severe BED with 8-13 binge eating episodes per week. Furthermore,
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only 17 of the patients that met DSM-5 criteria were diagnosed with either ICD-10 code F50.8 or
R63.2, leaving 21 patients without a diagnosis of binge eating disorder (see Figure 1).
Figure 1
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Comorbidity levels were also compared in those with BED and those without BED in
effort to determine if there was an increase in comorbidities associated with BED. The categories
analyzed included depression, other psychological disorders, hypertension, dyslipidemia,
diabetes type 2, metabolic syndrome, osteoarthritis and obstructive sleep disorder Those with
BED were found to experience higher levels of comorbid disorders than those without BED in
all but one category (see Figure 2).
Figure 2
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As shown in the literature, evidence-based treatments for those with BED include both
psychotherapeutic and pharmacologic methods. BED patients provided with, or referred to,
psychological/behavioral interventions was only 2.6 percent, surprisingly as this is recommended
as the first-line intervention shown to reduce binge frequency and increase abstinence in those
with BED. Evidence-based medications shown to improve symptoms of BED include
topiramate, lisdexamfetamine and non-BED specific SSRI/SNRIs. Of the 38 BED patients, 23.7
percent were prescribed topiramate, none of the patients were provided lisdexamfetamine and
36.8 percent were taking an SSRI or SNRI although for reasons other than BED. In regards to
non-evidence-based treatments, anti-obesity medications were prescribed to 44.7 percent of BED
patients, a dietician consult to 50 percent and suggestive behavior modification to 81.6 percent
(see Figure 3).
The retrospective analysis of the weight management center demonstrates that sufferers
of binge eating disorder are significantly under diagnosed and lacked evidence-based
interventions shown to reduce, or eliminate, the effects of BED.
Figure 3
Evidence-Based Treatments Recommended for Binge Eating Disorder
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The retrospective analysis of the weight management center demonstrates that sufferers
of binge eating disorder are significantly under diagnosed and lacked evidence-based
interventions shown to reduce, or eliminate, the effects of BED.
Cost Benefit Analysis
As mentioned, 21 of the 38 patients were not diagnosed with a billable ICD 10 code for
binge eating disorder, which leaves the weight management center with potential lost income.
According to the Butterfly Foundation of Eating Disorders (2015), the cost of BED treatment
under optimal intervention is $5,715 annually. An additional, analysis by Bellows, et al (2015)
found outpatient costs for one year of BED treatment at $5,730. Using the average of the two
findings, the average cost, or potential income, for each patient diagnosed with a billable ICD 10
code for BED is $5,722.50. Given that 21 patients were not provided an ICD code in the 9-month
analysis period, the income lost to this clinic during this time is approximately $120,173. This
could lead to approximately $160,230 for a 12-month period.
Discussion
The prevalence of binge eating disorder in this weight management clinic is 27.5 percent,
which is significantly higher than the general population. Unfortunately, those who meet the
DSM-5 criteria for BED are not being effectively coded which further leads to under-treatment,
ongoing illness and comorbidities, and lack of productivity which correlates with increased
health care costs of nearly $20,970 per person (Butterfly Foundation, 2015). Recognizing these
factors demonstrate the need for increased screening methods in both weight management and
primary care settings. By doing so, BED patients will be increasingly recognized and further
provided vital treatments necessary to overcome not only BED, but also the comorbidities related
to it.
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Implications for Practice
Binge eating disorder is likely to be more prevalent in both the primary and specialty care
settings where a large percentage of patients are obese. The under diagnosed problem may be
hidden underneath the guise of being overweight and the problem never discussed. This can pose
a significant problem in assisting those with BED ensuring the appropriate treatment and
attaining a healthy weight and lifestyle. With proper screening and referrals in the primary care
setting, providers can optimize the likelihood patients obtain evidence-based treatments.
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